Dr. Michael E. Jung, UCLA Jonsson Comprehensive Cancer Center member and Distinguished Professor of Chemistry and Biochemistry, has been elected a 2014 NAI Fellow by the National Academy of Inventors. The high honor is bestowed upon academic leaders who have demonstrated a prolific spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development and the welfare of society.
A world-renowned authority on synthetic organic and medicinal chemistry, Jung has more than 55 patents and/or patent applications arising from his research and consulting activities. He is a co-inventor of Xtandi®, an effective new therapy for patients with metastatic castration-resistant prostate cancer who no longer respond to medical or surgical treatments, and ARN-509, a drug in phase 3 clinical trials for non-metastatic, castration-resistant prostate cancer.
Jung joined the faculty at UCLA in 1974, and is now director of the UCLA Bioscience Synthetic Chemistry Core Facility. He is a cofounder of several companies and consults for more than 20 industrial biotech laboratories. He has published more than 330 journal articles and given over 570 lectures on his research.
The 2014 NAI Fellows will be inducted by the Deputy U.S. Commissioner for Patent Operations, from the United States Patent and Trademark Office during the 4th Annual Conference of the National Academy of Inventors, on March 20, 2015, at the California Institute of Technology in Pasadena.
With its 2014 class of inductees, the total number of National Academy of Inventors Fellows will now be 414, representing more than 150 prestigious research universities and governmental and non-profit research institutions.
